https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-01598
Olaparib, Durvalumab, and Tremelimumab in Treating Patients with Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer with BRCA1 or...
olaparibdurvalumabtremelimumabtreatingpatients
https://ascopost.com/news/november-2025/fda-approves-durvalumab-with-flot-for-resectable-gastric-gej-adenocarcinoma/
On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and...
fdadurvalumabflotresectablegastric
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT03660826&r=1
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory...
the combinationtestingolaparibdurvalumabcediranib
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2020-09850&r=1
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
testingadditiondurvalumabchemotherapysurgery
https://www.fda.gov/drugs/resources-information-approved-drugs/durvalumab-imfinzi
durvalumabimfinzifda
https://www.mountsinai.org/clinical-trials/testing-combination-of-olaparib-durvalumab-cediranib-durvalumab-olaparib-capivasertib-cediranib-alone-in-recurrent-refractory-endometrial-cancer-following-earlier-phase-of-study-that-tested-olaparib-cediranib-in-comparison-to-cediranib-alone-olaparib-alone
the combinationtestingolaparibdurvalumabcediranib